ReviewPharmaceutics2020
Progress of Cancer Nanotechnology as Diagnostics, Therapeutics, and Theranostics Nanomedicine: Preclinical Promise and Translational Challenges.
Review in Pharmaceutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Bio-magnetic nanomedicine for targeted drug delivery of breast cancer: green synthesis, functional design, and translational challenges.Breast cancer research : BCR · 2026Review
- Functionalized nanomedicines for co-targeting of multiple pathways to efficiently treat thyroid cancer: prospects and challenges.Frontiers in pharmacology · 2026Review
- Tumor microenvironment conversion through intelligent nanomedicine: a paradigm shift in overcoming chemoresistance.Frontiers in oncology · 2026Review
- Review of Recent Medicinal Applications of Rhenium(I) Tricarbonyl Complexes.International journal of molecular sciences · 2025Review
- In situ radiochemical doping of functionalized inorganic nanoplatforms for theranostic applications: a paradigm shift in nanooncology.Journal of nanobiotechnology · 2025Review
- A methotrexate labelled dual metal oxide nanocomposite for long-lasting anti-cancer theranostics.Materials today. Bio · 2025Article
- Nanotechnology-based biomedical devices in the cancer diagnostics and therapy.Medical oncology (Northwood, London, England) · 2025Review
- Nanotheranostics: A Cutting-edge Technology for Cancer Management.Current pharmaceutical biotechnology · 2025Review
- Theranostic Role of Advanced Nanotechnological Tools in Early Brain Metastases in Lung Cancer: An Updated Review.International journal of nanomedicine · 2025Review
- Advancements in Nanocarrier Delivery Systems for Photodynamic Therapy in Lung Cancer.International journal of nanomedicine · 2025Review
- Recent advances in the bench-to-bedside translation of cancer nanomedicines.Acta pharmaceutica Sinica. B · 2025Review
- Silica nanoparticle design for colorectal cancer treatment: Recent progress and clinical potential.World journal of clinical oncology · 2024Article
- Novel Drug Delivery Systems: An Important Direction for Drug Innovation Research and Development.Pharmaceutics · 2024Review
- Recent nanotheranostic approaches in cancer research.Clinical and experimental medicine · 2024Review
- Nanotechnological Advances in the Diagnosis of Gynecological Cancers and Nanotheranostics.Current pharmaceutical design · 2024Review
- Recent Advancements in Nanocarrier-assisted Brain Delivery of Phytochemicals Against Neurological Diseases.Neurochemical research · 2023Review
- Bladder microenvironment actuated proteomotors with ammonia amplification for enhanced cancer treatment.Acta pharmaceutica Sinica. B · 2023Article
- Molecularly Imprinted Carriers for Diagnostics and Therapy-A Critical Appraisal.Pharmaceutics · 2023Review
- Cancer nanomedicine: a review of nano-therapeutics and challenges ahead.RSC advances · 2023Review
- Oral Bioactive Self-Nanoemulsifying Drug Delivery Systems of Remdesivir and Baricitinib: A Paradigmatic Case of Drug Repositioning for Cancer Management.Molecules (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Early detection, right therapeutic intervention, and simultaneous effectiveness mapping are considered the critical factors in successful cancer therapy. Nevertheless, these factors experience the limitations of conventional cancer diagnostics and therapeutics delivery approaches. Along with providing the targeted therapeutics delivery, advances in nanomedicines have allowed the combination of therapy and diagnostics in a single system (called cancer theranostics). This paper discusses the progress in the pre-clinical and clinical development of therapeutics, diagnostics, and theranostics cancer nanomedicines. It has been well evident that compared to the overabundance of works that claimed success in pre-clinical studies, merely 15 and around 75 cancer nanomedicines are approved, and currently under clinical trials, respectively. Thus, we also brief the critical bottlenecks in the successful clinical translation of cancer nanomedicines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.